Previous 10 | Next 10 |
home / stock / lmngf / lmngf news
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone Canada NewsWire VANCOUVER, British Columbia , Sept. 17, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ( "BioVaxys"), announced today that ...
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs Canada NewsWire VANCOUVER, BC , Sept. 14, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ...
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH Canada NewsWire VANCOUVER, British Columbia , July 22, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ( "B...
BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development Canada NewsWire VANCOUVER, British Columbia , June 14, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ( "BioVaxys"), is ple...
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study Canada NewsWire VANCOUVER, BC and LYON, France , June 1, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (...
Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing PR Newswire VANCOUVER, British Columbia , May 24, 2021 /PRNewswire/ -- BioVaxys Technology Corp. ( CSE: BIOV, FRA...
BioVaxys Announces Appointment of Policy Advisor Canada NewsWire VANCOUVER, BC , May 20, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:BVAXF) ( "BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platfor...
BioVaxys Announces Uplisting To The OCTQB Venture Market Canada NewsWire VANCOUVER, BC , May 19, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and c...
Palm Beach, FL – May 3, 2021 Ovarian cancer is the 8th most common cancer among women and ranks 5th in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. The three major types of ovarian cancer are epithelial, accounting for...
BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction Canada NewsWire VANCOUVER, BC , May 3, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF ) ( "BioVaxys" or...
News, Short Squeeze, Breakout and More Instantly...
BioVaxys Announces New Chief Financial Officer Canada NewsWire VANCOUVER, BC , Sept. 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Craig Loverock ha...
BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in vivo animal study Canada NewsWire VANCOUVER, BC , Sept. 6, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys...
BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT Canada NewsWire VANCOUVER, B.C. , Aug. 2, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") further to its news release dated July 4, 2022 , Bi...